Leiomyosarcoma of penis

Khobragade, Krunal; Tamhankar, Ashwin Sunil; Bakshi, GK; Tongaonkar, HB; Menon, Santosh

doi:10.4103/0019-509x.176719

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer is the sixth leading cause of cancer death among men worldwide and the fifth highest incidence rate among males in India in 2016. 4 5 In high-risk prostate cancer, 68 Ga-PSMA-11 PET/CT is known to be a useful method for the detection of metastases. 6 Associated with the rise of prostate cancer, use of PSMA-PET/CT has been indicated for staging in high-risk prostate cancer, response assessment after therapeutic interventions in correlation with serum PSA levels, and evaluating biochemical recurrence and prior to planning patients for 177 Lu-PSMA-617 therapy.…”

Section: Discussionmentioning

confidence: 99%

Concomitant Bilateral Inferior Gluteal Lymph Node Involvement in Metastatic Prostate Adenocarcinoma Detected on 68Gallium-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography

Baberwal,

Sonavane,

Basu

2024

World J Nucl Med

View full text Add to dashboard Cite

An unusual and unique case of prostate adenocarcinoma with involvement of bilateral inferior gluteal lymph nodes is reported. The patient was a 42-year-old male, with conventional prostatic adenocarcinoma (Gleason score: 5 + 4 = 9), who, during disease progression with rising serum prostate specific antigen levels following medical androgen deprivation therapy, demonstrated new prostate-specific membrane antigen expressing metastatic intermuscular deposits in the bilateral gluteal region, subsequently proven to be bilateral inferior gluteal nodal metastasis. A therapeutic implication to this may be that these nodes usually fall beyond the range covered by the therapeutic radiation field coverage where external radiotherapy is the advocated modality of choice and are not easily reachable through standard surgical procedures. As a result, they could have an impact on the way patients are clinically treated and on their prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Concomitant Bilateral Inferior Gluteal Lymph Node Involvement in Metastatic Prostate Adenocarcinoma Detected on 68Gallium-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography

Baberwal,

Sonavane,

Basu

2024

World J Nucl Med

View full text Add to dashboard Cite

show abstract

“…A study by Murthy et al was the first of its kind on prostate cancer in India. However, the issue of HDR prostate cancer BT was not considered in detail [12,14].…”

Section: Discussionmentioning

confidence: 99%

Current status and future readiness of Indian radiation oncologists to embrace prostate high-dose-rate brachytherapy: An Indian Brachytherapy Society survey

Banerjee,

Sarkar,

Mahantshetty

et al. 2023

jcb

View full text Add to dashboard Cite

Purpose This survey aimed to understand the practice pattern and attitude of Indian doctors towards prostate brachytherapy. Material and methods A 21-point questionnaire was designed in Google form and sent to radiation oncologists practicing in India, using texts, mails, and social media. Responses were collated, and descriptive statistical analysis was performed. Results A total of 212 radiation oncologists from 136 centers responded to the survey questionnaire, with majority (66%) being post-specialty training > 6 years. We found that about 44.3% ( n = 94) of respondents do not practice interstitial brachytherapy for any site, and majority (83.3%, n = 175) do not practice high-dose-rate (HDR) prostate brachytherapy. Only 2.8% ( n = 6) of doctors preferred boost by brachytherapy compared with 38.1% ( n = 80) of respondents, who favored stereotactic body radiation therapy (SBRT) boost. When asked about the indication of HDR prostate brachytherapy in Indian setting, 32.5% ( n = 67) of respondents favored monotherapy, 46.1% ( n = 95) of oncologists thought boost as a good indication, and 21.4% ( n = 44) preferred re-irradiation/salvage setting. The most cited reason for prostate brachytherapy not being popularly practiced in India was lack of training (84.8%, n = 179). It was also noted that out of 80 respondents who practiced SBRT for prostate boost, 37 would prefer HDR brachytherapy boost if given adequate training and facilities. Conclusions The present survey provided insight on practice of prostate brachytherapy in India. It is evident that majority of radiation oncologists do not practice HDR prostate brachytherapy due to lack of training and infrastructure. Indian physicians are willing to learn and start prostate brachytherapy procedures if dedicated training and workshops are organized.

show abstract

Leiomyosarkom der Vorhaut

Rabinovich¹

2018

Urologe

View full text Add to dashboard Cite

We report a case of a rare mesenchymal foreskin tumor. A slow-growing node was detected during the urological examination of a 39-year-old man. A histological examination following the node excision showed a superficial leiomyosarcoma. Superficial leiomyosarcomas rarely metastasize and are associated with a better prognosis than deeper tumors. The patient had no relapse 9 months after a successful radical circumcision. We strongly recommend a histological examination whenever a growing node in the genital area is found.

show abstract

Leiomyosarcoma of penis

Cited by 4 publications

References 0 publications

Concomitant Bilateral Inferior Gluteal Lymph Node Involvement in Metastatic Prostate Adenocarcinoma Detected on 68Gallium-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography

Concomitant Bilateral Inferior Gluteal Lymph Node Involvement in Metastatic Prostate Adenocarcinoma Detected on 68Gallium-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography

Current status and future readiness of Indian radiation oncologists to embrace prostate high-dose-rate brachytherapy: An Indian Brachytherapy Society survey

Leiomyosarkom der Vorhaut

Contact Info

Product

Resources

About